Eli Lilly (NYSE:LLY) shares snapped six straight days of losses as the stock closed 1.39% higher, at $812.76 on Friday.  The ...

Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Mehmet Oz, MD, President Donald Trump's pick for CMS administrator, sat through three hours of questioning March 14 from the Senate Finance Committee.